126
Participants
Start Date
July 1, 2025
Primary Completion Date
December 26, 2026
Study Completion Date
December 30, 2026
Trelagliptin 100 mg
Trelagliptin will be administered as oral tablets at a dose of 100 mg once weekly for 3 months. Participants will continue background metformin therapy as prescribed. Trelagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor indicated for type 2 diabetes mellitus and differs from daily DPP-4 inhibitors due to its longer duration of action, allowing weekly dosing.
Sitagliptin 100mg OD
Sitagliptin will be administered as oral tablets at a dose of 100 mg once daily for 3 months. Participants will continue background metformin therapy as prescribed. Sitagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor indicated for type 2 diabetes mellitus and requires daily dosing.
Khyber Teaching Hospital / Khyber Medical College, Peshawar
Khyber Medical College, Peshawar
OTHER